Testing a new drug for people with certain autoimmune diseases that have come back or not responded to treatment
Treatments studied
Part of Immune system & allergy clinical trials.
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with one of these autoimmune diseases: systemic lupus erythematosus, diffuse systemic sclerosis (hardening of the skin), inflammatory myopathy (muscle inflammation), or autoimmune bullous dermatosis (blistering skin disease).
- Your disease has come back (relapsed) or has not responded to previous treatments (refractory).
- Your major organs (like heart, lungs, liver, kidneys) must be working well enough.
- You cannot have had a heart attack, heart failure, or other serious heart problems in the last 6 months, and no cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This trial tests an experimental medicine called HN2302 in people with certain autoimmune diseases like lupus or scleroderma. The goal is to see if it is safe and if it can help reduce disease activity, which might improve symptoms.
This trial tests an experimental injection (called WGb-0301) to see if it can help people with autoimmune diseases like lupus or scleroderma that have not improved with usual treatments. The goal is to find a new option for those who have run out of standard therapies.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
Hear when a new Autoimmune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.